LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Stryker Replaces International Group President
People In The News

Stryker Replaces International Group President

August 30, 2011 1 min read Premium comments

Advertisement

Stryker Replaces International Group President
Ramesh Subrahmanian/Stryker Corp.

Stryker Corporation has nabbed Merck & Co.’s top executive from Asia Pacific to become the company’s new Group President, International. 

Ramesh Subrahmanian, the former senior vice president and president, Asia Pacific for Merck & Co, was named to the position on August 18. He replaces Andrew Fox, who is leaving, according to a company statement, “to pursue other career opportunities.” His appointment is effective September 1, 2011.

Stryker’s total sales outside the U.S. in 2010 were $2.527 billion. That was a 5% increase over 2009, but well below 11% sales growth in the U.S. Stryker will certainly be looking to ramp up international sales as competitors target those emerging markets.

Stephen MacMillan, Stryker’s CPCEO (chairman, president and CEO) said, “Subrahmanian brings a “strong global perspective to Stryker through his successful leadership roles in the U.S., Germany, India and Asia Pacific. He is a proven healthcare leader who has demonstrated the ability to drive profitable growth and innovation, and we look forward to taking advantage of his varied experiences as we continue to grow our international businesses, “

Subrahmanian spent 23 years in the pharmaceutical industry where held various senior level jobs. In addition to Merck, he worked for Sanofi-Aventis and Hoechst Marion Rousel Ltd. At Stryker, he will have responsibilities for all the company’s international business and work out of Singapore.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy